Literature DB >> 499297

Disposition pharmacokinetics of bezafibrate in man.

U Abshagen, W Bablok, K Koch, P D Lang, H A Schmidt, M Senn, H Stork.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 499297     DOI： 10.1007/bf00644963

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  [Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)].

Authors:  O Adam; G Wolfram; P D Lang; N Zöllner
Journal:  MMW Munch Med Wochenschr       Date:  1979-03-02

2.  [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].

Authors:  A Cailleux; P Allain; A Tadei
Journal:  Therapie       Date:  1976 Sep-Oct       Impact factor: 2.070

3.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

Authors:  A G Olsson; S Rössner; G Walldius; L A Carlson; P D Lang
Journal:  Atherosclerosis       Date:  1977-07       Impact factor: 5.162

5.  Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.

Authors:  A G Olsson; P D Lang
Journal:  Atherosclerosis       Date:  1978-12       Impact factor: 5.162

6.  Mass spectral analysis of glucuronides.

Authors:  S Billets; P S Lietman; C Fenselau
Journal:  J Med Chem       Date:  1973-01       Impact factor: 7.446

7.  [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].

Authors:  H R Arntz; U H Klemens; L J Vollmar; P D Lang
Journal:  Med Klin       Date:  1978-12-08

8.  [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].

Authors:  K Bolzano; F Krempler; B Schellenberg; G Schlierf
Journal:  Acta Med Austriaca       Date:  1979

9.  Pharmacokinetics of clofibrate in familial hypercholesterolemia.

Authors:  R Pichardo; L Boulet; J Davignon
Journal:  Atherosclerosis       Date:  1977-04       Impact factor: 5.162

10.  [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)].

Authors:  P Wahl; C Hasslacher; P D Lang; J Vollmar
Journal:  Dtsch Med Wochenschr       Date:  1978-08-04       Impact factor: 0.628
View more
  16 in total

1.  Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients.

Authors:  G Neugebauer; D Platt; T Vömel; W Lösch
Journal:  Klin Wochenschr       Date:  1988-03-15

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

3.  Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.

Authors:  U Abshagen; W Kösters; B Kaufmann; P D Lang
Journal:  Klin Wochenschr       Date:  1980-09-01

Review 4.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

6.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

8.  Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Authors:  Lauri I Kajosaari; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

9.  Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.

Authors:  P Anderson; H E Norbeck
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.

Authors:  Takero Nakajima; Naoki Tanaka; Hiroki Kanbe; Atsushi Hara; Yuji Kamijo; Xiaowei Zhang; Frank J Gonzalez; Toshifumi Aoyama
Journal:  Mol Pharmacol       Date:  2009-01-05       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.